For the first time, we demonstrated that immune modulation by neutrophils in AIS and AMI could potentially target ITGAM, CD163, ARG1, HIF1A, and ACSL1, thereby establishing a theoretical rationale for immune-targeted interventions in AIS and AMI. This evidence concerns the gene ITGAM and androgen insensitivity syndrome.